Drugs / Micronized purified flavonoid fraction
Micronized purified flavonoid fraction
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT06184438 | Dec 2023 → Jan 2025 | anal fistula | Taipei Medical University Shuang Ho Hospital | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT06363513 | Apr → May 2024 | rectal disorder | Chiang Mai University | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT06584799 Comparator | Dec 2024 → Jan 2025 overdue | pelvic congestion syndrome | Pirogov Russian National Research Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT03833024 Comparator | Feb 2022 → Mar 2024 | post-thrombotic syndrome | Sir Mortimer B. Davis - Jewish General Hospital | Unknown | No outcome recorded |
| — | NCT06560294 Comparator | Aug 2024 → Oct 2025 overdue | pelvic congestion syndrome | Tanta University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Micronized purified flavonoid fraction | “Micronized Purified Flavonoid Fraction (MPFF), integral to hemorrhoid treatment, has been scrutinized for its ability to mitigate pathogenic processes culminating in acute bleeding.” NCT06363513 ↗ |
| Known as | Daflon | “Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.” NCT06560294 ↗1“Micronized purified flavonoid fraction(Daflon 1000mg)” NCT06184438 ↗ |
| Known as | MPFF | “Micronized Purified Flavonoid Fraction (MPFF, Venixxa), a venoactive drug, has been reported to be effective in reducing venous symptoms and signs and improving QOL in patients...” NCT03833024 ↗ |
| Known as | Venixxa | “Micronized Purified Flavonoid Fraction (MPFF, Venixxa), a venoactive drug, has been reported to be effective in reducing venous symptoms and signs and improving QOL in patients...” NCT03833024 ↗ |
| Route | Oral | “1000 mg of oral MPFF (Venixxa, one 500mg tablet BID)” NCT03833024 ↗ |